Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02902874

Acronym

Immuno ALCL

Enrollment

185

Registered

2016-09-16

Start date

2010-04-21

Completion date

2020-12-31

Last updated

2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALCL

Brief summary

To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Interventions

OTHERBlood sample

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Every patients treated according to COPAD-IGR, HM 89,91 and 97 and ALCL99 protocols and included in related studies * Clinical data registered in SFCE database * Signed consent form

Exclusion criteria

* No ALK expression on tumour * No consent signed

Design outcomes

Primary

Measure	Time frame
Number of single nucleotide polymorphisms in main immunogenicity genes using VERACODE ILLUMINA technology	up to 78 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026